TEK and ovarian cancer: We reported recently that ovarian cancer patients with supra-median plasma concentrations of Ang1 and infra-median concentrations of Tie2 benefited from bevacizumab (Backen et al, 2014), whereas those with raised concentrations of both circulating angiogenesis-associated biomarkers or infra-median concentrations of Ang1 did not benefit.